Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet.
Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is that Oxford BioMedica will develop and supply GMP-grade lentiviral vectors with exclusive IP licenses that Orchard will use in its ex-vivo stem cell gene therapies for rare diseases.
In exchange, Oxford Biomedica will receive a 1.95% equity stake in Orchard and performance incentives that could double this number. Additionally, the Oxford-based company will receive royalties on future sales of products arising from the collaboration.
The main targets of Orchard’s ex-vivo gene therapies are adenosine deaminase severe combined immunodeficiency (ADA-SCID) and Sanfilippo Syndrome type A. The new team will then be competing with Lysogene, one of the coolest biotechs in Paris, which was started by Karen Aiach,